LBT Innovations Limited (AU:LBT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LBT Innovations Limited has achieved a significant milestone by selling its APAS® Independence, an AI-driven microbiology automation system, to Bristol Myers Squibb in the United States. This marks the first sale to a pharmaceutical customer in the US, reflecting growing interest and demand in the sector. The sale is part of LBT’s strategy to engage with large pharmaceutical companies, highlighting the potential of their technology to enhance microbiology operations.
For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.